

MICROBIOLOGY
IN
PHARMACEUTICAL
MANUFACTURING

SECOND EDITION
REVISED AND EXPANDED



Richard Prince
Editor
VOLUME 2

CONTENTS

	Introduction	xv
	<i>Richard Prince</i>	
15	Safety Ventilation in Cleanrooms	I
	<i>Bengt Ljungqvist and Berit Reinmüller</i>	
	Introduction	1
	Dispersion of Airborne Contaminants	2
	People as a Contamination Source	3
	Clothing Systems	3
	Turbulent Mixing Air	4
	Downward (Vertical) Unidirectional Air Flow	6
	Risk Assessment with the LR-Method	8
	Risk Assessment	8
	The Method for the Limitation-of-Risks (LR Method)	9
	Case Studies from Aseptic Filling Lines	9
	Discussion	14
	References	16
	About the Authors	17

16	Environmental Monitoring	19
	<i>Jeanne Moldenhauer</i>	
	Overview	19
	Components of an Environmental Control System	20
	Facility Design and Maintenance	21
	Documentation Systems and Procedural Controls	21
	Procedural Controls	21
	US Requirements	22
	Buildings and Facilities	22
	Personnel	22
	Laboratory Controls	23
	European Requirements	25
	General Requirements	26
	Documentation	26
	Blow Fill Seal (BFS)	26
	Terminally Sterilized Products	26
	Aseptic Preparations	27
	Personnel	27
	Premises	28
	Equipment	29
	Processing	29
	Microbiological Monitoring	30
	Laboratory Control Records	30
	Sampling and Testing of Incoming Production Materials	30
	Laboratory Controls	30
	World Health Organization (WHO)	31
	Quality Control	31
	Validation	31
	Documentation	31
	Supporting and Supplementary Guidelines	32
	Japanese Requirements	33
	Quality System	33
	Training and Education	34
	Routine Monitoring and Control	34
	Personnel	35
	Prevention of Contamination by Personnel	35
	Buildings and Facilities	35
	Processing Areas of Sterile Drug Products	35
	Cleaning and Disinfection of Processing Areas	36
	Environmental and Personnel Monitoring	37
	Isolators	38
	Blow-Fill-Seal Operations (BFS)	39
	Active Pharmaceutical Ingredients (APIs)	39

Contents

v

Data Management	39
Cleaning, Sanitization, and Disinfection	40
Environmental Process Control Parameters	41
Basic Parameters of an Environmental Monitoring Regime	41
Environmental Monitoring System Selection	41
Method Validation/Implementation	42
Selection of Sample Sites	42
Environmental Monitoring Sampling Frequency	43
Alert and Action Levels	44
Analytical Method Variability	44
Risk Assessment	45
Data Management	45
General Methods for Assessing the State of Environmental Control	57
Interpretation of Environmental Data	59
Characterization (Identification) of Isolates Recovered	60
Deviation Reports/Investigations/Corrective Actions	61
Typical Surveillance Programs	61
Water Monitoring	61
Compressed Gas Monitoring	63
Air Monitoring	65
Nonviable Monitoring	65
Viable Monitoring	67
Surface Monitoring	67
Personnel Monitoring	68
Parametric Release and Bioburden	69
Validation of Aseptic Processes — Media Fills (Process Simulation Trials)	69
Maintenance of a Surveillance Monitoring Program	70
Terminal Sterilization	70
Aseptic Filling	70
Isolation Technology	70
In-Process Testing	71
Special Concerns for Monitoring During Routine Sterility Testing	71
Acknowledgements	89
References	89
About the Author	91

17	Disinfectants Program	93
	<i>Paul K. Priscott and Yung Dai</i>	
	Available Disinfectants and Antiseptics	94
	To Rotate or What to Rotate — Now That is a Question!	100

vi *Microbiology in Pharmaceutical Manufacturing — Volume 2*

A Plan for Qualifying Disinfectants in Your Plant	101
Non-sterile Manufacturing Facilities	101
Sterile Manufacturing Facilities	101
Efficacy Testing	104
AOAC Use-Dilution Method	105
AOAC Hard Surface Carrier Test Method	105
AOAC Germicidal Spray Products Method	105
AOAC Fungicidal Activity of Disinfectants Test	105
AOAC Tuberculocidal Activity Method	106
EPA Quantitative Tuberculocidal Suspension Method	106
AOAC Sporicidal Activity of Disinfectants Test (Methods I and II)	106
Quantitative Three Step Method for Sporicidal Activity	106
ASTM Time-Kill Procedure	107
ASTM Virucidal Test Methods	107
Other Methods	109
Adaptations of Standard Methods for Disinfectant In-Use Qualification Studies	109
References	109
About the Authors	113

18 Training of Aseptic Processing Personnel 115

James L. Vesper

Why Focus on People?	116
The Right People for the Job	116
Equipping the Person to do the Job, Part 1: Defining the Competencies	117
Equipping the Person to do the Job: Part 2: Providing Knowledge and Skills	119
Creating Learning Plans (Curricula)	121
Topics to Include in the Curricula	123
Instructional Methods	123
Hands-on Learning	127
Periodic/Reinforcement Training	127
Assessment of Learner Knowledge and Performance	129
Qualification? Certification?	131
Learning From Successes and Failures	131
Conclusion	132
Acknowledgements	132
References	132
Appendix One	134
About the Author	141

19	The Global State of Microbiological Compendial Methods	143
	<i>Scott Sutton</i>	
	Introduction	143
	Antimicrobial Effectiveness Tests	145
	Bacterial Endotoxins Tests	148
	Microbial Limits Tests	149
	Harmonization History	149
	Microbial Enumeration Test	151
	Absence of Specified Microorganisms	151
	Implementation	161
	Sterility Tests	162
	Conclusion	163
	Acknowledgements	164
	References	164
	About the Author	169
20	Rapid Microbiological Methods	171
	<i>Michael J. Miller</i>	
	Introduction	171
	The Desired State of Pharmaceutical Manufacturing	173
	Science and Technology	174
	Economics	174
	Regulatory and Compendial Acceptance	176
	Encouragement from the Pharmacopeias	176
	Applications and Opportunities	177
	Technology Platforms	179
	Growth-based Technologies	180
	Viability-based Technologies	181
	Artifact-based Technologies	182
	Nucleic Acid-based Technologies	184
	Micro-Electro-Mechanical Systems (MEMS)	187
	Summary and Closing Remarks	189
	References	217
	About the Author	221
21	New Technologies for Microbiological Testing	223
	<i>Anthony M. Cundell</i>	
	Introduction	223
	Evaluation of New Technologies	224
	Selection of the Appropriate Rapid Microbial Method	225
	Examples of New Microbiological Testing Methods	227

viii *Microbiology in Pharmaceutical Manufacturing — Volume 2*

Proof-of-Concept Studies	230
Financial Justification	230
Method Development and Validation	231
Regulatory Filings	233
Promising New Technologies	237
Conclusion	241
References	241
About the Author	243

22 **Bacterial Endotoxin Test** **245**

James F. Cooper

Pyrogenicity	245
Bacterial Endotoxins	246
Emergence of the Bacterial Endotoxins Test	247
Endotoxin Limit (EL)	248
LAL Reaction with Endotoxin and Interference Conditions	250
Standardized LAL-Test Methods	251
Harmonized BET (USP <85>)	252
Photometric Methods	252
Kinetic Readers and Endotoxin-Specific Software	253
Validation of Bacterial Endotoxins Test Methods	255
Product Description	256
Reagent Suitability and pH Studies	256
Compatibility Profile and Concentration	257
Defined Validation Conditions	258
BET Validation Report	259
Pyrogenicity Outbreaks	260
Validation of Depyrogenation Processes	261
Pharmaceutical Waters	261
Glassware	262
Elastomeric Closures	263
Components	264
BET Applications	265
Large Volume Parenterals (LVPs)	265
Small Volume Parenterals (SVPs)	265
Biologicals	266
Medical Devices	267
LAL-Reactive Glucan (LRG)	268
Spinal Infusions	268
Excipients	268
Acknowledgement	269

References	270
About the Author	273
23 Microbial Limits Test Program	275
<i>Michael C. Carroll</i>	
Product Overview	277
Sampling	280
Media Preparation and Qualification	281
Preparatory Testing	281
Qualitative (“Absence of”) Testing	288
Methods	292
Conclusion	293
References	293
About the Author	294
24 Stability Program with Microbiological Points to Consider Throughout Drug Development	295
<i>Hannah Monds and Robert Guardino</i>	
Introduction	295
The Drug Development Process	297
Stability Protocol Design	298
Storage Conditions	298
Batch Selection	299
Testing Schedule and Specifications	301
Container/Closure System	301
Distributing Stability Samples	303
Managing the Stability Program	306
Microbiological Aspects of the Stability Program	306
Stability Requirements Related to Microbial Contamination and Control	308
Effect of Storage Conditions and Post-Pull Handling on Microbiological Testing	312
Conclusion	313
References	313
About the Authors	315
25 Management of Deviations	317
<i>Marianne Scheffler</i>	
Laboratory Deviations	321
Measure the Deviation for Trends	325

x *Microbiology in Pharmaceutical Manufacturing — Volume 2*

Quality Self-Assessment Audits	325
Corrective Action and Preventative Action Plans (CAPA)	327
Summary for Managing Deviations	329
References	329
Definitions	330
About the Author	333

26 Modern Quality Systems 335

Richard L. Friedman

Introduction	335
1. Global Quality Assurance	336
2. Quality Foundation	337
Quality Leadership and Commitment	338
Trend Today, Improve Tomorrow	339
3. Good Science	339
4. Intended Use	341
5. People: Qualifications, Roles, Responsibilities	342
6. Reliable Laboratory	343
7. Suitability of Equipment, Facilities, and Associated Procedures	344
A Day in the Life: Minimizing Variability	344
Same Way, Each Time	345
Quality–Business Synergy	345
8. Raw Material Quality and Surveillance	346
9. Batch Review and Release	347
10. Documentation	349
11. Effective Development and Process Validation	349
From Development to Commercialization	349
Life Cycle Progression: Monitoring Regular Production	351
12. “Building Quality In” and the Willingness to Fix a Flawed Process	353
13. Effective Use of Risk Assessment	355
Advantages of Risk Assessment Methods	355
Quantity of Data Used to Assess Risk	355
Quality of Data: Adequacy of the Risk Assessment	357
Regulatory Concepts	357
14. Understanding Sources of Variability and Signals of Drift	360
Sources of Variability and Risk Mitigation	360
Why Drift Occurs	361
We’ve Always Done It That Way	363
Testing a Finished Product	363
Preventing Drift: Detect, Correct, Prevent	364

Contents **xi**

15. Awareness of the Link Between Safety, Efficacy, and Quality	364
16. The Quality Organization: Authority, Responsibility, and Accountability	365
Quality Management Metrics	366
17. Taking Action When Necessary	367
18. Internal Audit Program	368
19. Contracting and Outsourcing Scrutiny	368
20. Modernization: Knowing the Current Science and Employing Contemporary Technology	369
Conclusion	370
References	371
About the Author	375
27 Regulatory Stewardship: The Global Regulatory Dossier for Parenteral Drugs	377
<i>Kip Vought</i>	
Introduction	377
Drug Substance (3.2.S)	380
Drug Product (3.2.P)	381
Description and Composition of the Drug Product (P.1)	381
Pharmaceutical Development (P.2)	381
Manufacture (P.3)	385
Control of Excipients (P.4)	387
Control of Drug Product (P.5)	388
Reference Standards or Materials (P.6)	388
Container Closure System (P.7)	388
Stability (P.8)	389
Conclusion	389
About the Author	389
28 Electrons and Microbes: Using the Internet to Advance the Field of Microbiology	391
<i>Scott Sutton</i>	
Web Sites	391
Search Engines	392
Associations on the Web	393
Regulatory Web Sites	395
Culture Collections	399
Journals on the Web	399
Web Sites Helpful with Training	403




xii *Microbiology in Pharmaceutical Manufacturing — Volume 2*

EMail Lists	403
EMail Newsletters	409
Usenet	411
Blogs	413
Summary	413
References	413
About the Author	414
29	History of Microbial Identification
	<i>Ziva Abraham</i>
Introduction	417
History of Microbiology and Microbial Identification	418
Taxonomy, Classification, Identification, and Nomenclature	419
Phenotypic Microbial Identification Systems	421
API Panels	421
Vitek® Microbial Identification Systems	425
Vitek 32	425
Vitek 2	426
Biolog™ System	427
MIDI Sherlock® Microbial Identification System using	
Fatty Acid Methyl Ester (FAME) Analysis	431
MIDI Sherlock® DNA Sequencing Software	433
MIDI Sherlock <i>Instant FAME</i> ™	433
Genotypic Systems	433
RiboPrinter® Microbial Characterization System	
(DuPont Qualicon)	435
Lysis, Deproteinization and Digestion	436
Separation and Transfer	436
Membrane Processing	436
Detection	436
Identification	437
Characterization	437
<i>Image 8-RiboPrinter</i>	437
MicroSeq® rDNA Gene Sequencing System for Microbial	
Identification	437
Microarray Technology	439
Fungal Identification	440
Validation of Microbial Identification Systems	440
Conclusion	442
Acknowledgements	442
References	442
About the Author	444

Contents

xiii

30	Aseptic Processing in the US and EU: Another Brick in the Wall	445
	<i>Martyn Becker</i>	
	About the Author	457
Index		459



INTRODUCTION

In the 1980s, we witnessed the beginning of the AIDS pandemic. It remains out of control in parts of the developing world. In the first decade of this century, we saw indicators of an avian influenza pandemic possibly one day ravaging humanity. What will happen in the next decade or two? What impact will climactic variability, whether “natural” or human-derived — have on microorganisms that cohabit our planet? Will it subtly change microbial ecosystems in a manner that will impinge upon eukaryotic ecosystems, including our own? Will the march of biotechnology soon lead to the plausible use of “designer genomes” that will benefit humans? And, if so, how will the community of microorganisms respond? I would guess in a way that reestablishes some degree of inter-species stability to neutralize the impact of human intervention. Regardless, we seem fated to continue to engineer new industrial approaches — including the recent, remarkable advances in creating synthetic microorganisms — intended to either safeguard our species from the ever-present danger of microorganisms or to leverage microorganisms themselves for some other useful benefit to humanity. We humans are endowed with a purpose. We now have the molecular biological methods to change the natural world to serve our purpose. A basic respect for microorganisms and the field of microbiology is thus in order!

The pharmaceutical industry exists to discover, develop, manufacture and distribute diagnostic and therapeutic products (drug; biologics) that will protect and advance human health. Some of these drugs (antibiotics) are designed to kill pathogenic microorganisms, some are designed to prevent disease in the first place

(vaccines) while yet others are intended to improve some type of biological performance. All drugs, biologics and allied products must be manufactured properly so that they themselves are not the carriers of disease and death. Microbes seemingly lurk everywhere. So, our task as an industry is to design, develop and implement quality systems that will be used in a manufacturing setting to help ensure that product batches are consistently made to all predefined quality attributes and specifications. But quality of course is more than just meeting specifications; it is attitudinal. Quality (as a discipline, as a field) is about — or should be about — identifying new, more sophisticated ways to maintaining and augmenting our assurance of the quality of the products that are commercially distributed. This is not an easy task given the scale and variability expressed in microbiological systems as well as the variability experienced in the systems used to manufacture, test and distribute such products. And even if we could outwit microorganisms (through technology, in particular) in our ability to consistently provide safe and efficacious products of highest possible quality, it can become somewhat moot given the uneven compliance practices of humans to dispense and administer such products at home. Microbes are like slippery eels that we seek to temporarily grab but we can't in fact hold on to for very long. We try to control them, even to conquer them, but for every new drug or biologic that satisfies an unmet clinical need, there is, as well, the steady sting of microbial mutation, of microbial resistance, and of primitive, prokaryotic defiance. Microbes, then, are friend and foe, a formidable intellectual and enduring professional challenge for the scientist, the ethicist and the philosopher.

In the first edition of this book, published in 2001, the reader was advised to think of microbiology in a comprehensive and systematic way. That book was very well received and argued the need for a second edition, which is hereby presented. If there is a message in this edition, it is this: Our health is a function of many variables, some within our control (e.g., living practices) and some beyond (e.g., our genetic make-up), and our ability to maintain or improve our health rests upon our humility to appreciate the fragility and variability of life, the difficulty in changing our ways, and the insidious, invisible, ubiquitous role played by microorganisms. We must be vigilant, but we must also be sensible in the things that we can do to meaningfully improve our quality of life. Our noble pursuit is to try and raise the bar on human longevity and wellness. Somewhere in that quest, we intersect with microorganisms, charged with their own ancient, ambivalent mission. We will need to summon all of our creative talents and wisdom to strike the proper balance between the conflicting human traits of hegemony and humility.

The second edition is largely modeled on the first edition. Many of the authors who contributed chapters in the first edition have updated their respective chapters for this edition. Some authors appear for the first time in this text. All of them are subject-matter experts in their respective fields, they are found throughout the regulated world, and all of them provide content that will be of practical benefit to the pharmaceutical and biologics industry, and all of its allied fields.

Volume 1 covers Chapters 1–14

- Phylogeny
- Epidemiology
- Taxonomy
- Industrial Microbiological Primer
- Parenteral Facility Engineering
- Process Capability and Product Specifications
- Control Strategies during Product Development
- Risk Assessment in Production Operations
- Designing and Validating a Contamination Control Program
- Control Strategies for Biological Processes
- Sterilization Process Validation
- Sterilizing Filtration of Liquids
- Cleaning Validation
- Water Microbiology.

Volume 2 covers Chapters 15–30

- Science of Particulates
- Environmental Monitoring
- Disinfectants and Other Chemical Germicides
- Training of Aseptic Processing Personnel
- Comparison of Global Compendial Methods
- Rapid Microbiological Technologies and Methods (two chapters)
- Bacterial Endotoxins Testing
- Microbial Limits Testing
- Stability Program
- Handling and Management of Deviations
- Modern Quality Systems
- Regulatory Stewardship: Global Regulatory Dossier
- Internet and Microbiology
- Expert Opinion on Aseptic Processing.

The goal of this book is to provide updated and expanded microbiological information for the benefit of a global audience of stakeholders. It is sincerely hoped that each reader will find some content that will aid in formulating keener questions as well as finding smarter solutions, in a way that brings credit to all.

Richard Prince
Short Hills, New Jersey USA
December 2007

